Phase II data shows strong immunogenicity for ID Biomedical's FluINsure

August 2003
PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p7
Market Research Report
Focuses on the clinical trials for FlulNsure, an intranasal, non-live, influenza vaccine developed by ID Biomedical Corp. Patients enrolled in the study; Presentation of the clinical study of FlulNsure; Evaluation on the efficacy of the influenza vaccine.


Related Articles

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • EFFICACY OF INFLUENZA VACCINE IN THE ELDERLY. Schwartz, Kendra // Journal of Family Practice;Mar1995, Vol. 40 Issue 3, p298 

    The article discusses research being done on the efficacy of influenza vaccines in elderly individuals. It references a study by T. M. E. Govaert et al published in the December 7, 1994 issue of "The Journal of the American Medical Association." Information is provided on the population studied....

  • Antigenic and genetic characteristics of H5N1 viruses and candidate vaccine viruses developed for potential use in human vaccines, February 2009.  // Weekly Epidemiological Record;2/27/2009, Vol. 84 Issue 9, p72 

    The article provides information on the characteristics of H5N1 viruses and cites the vaccines that are being developed for their prevention. According to the article, these viruses are considered as endemic in other nation and still spreading infections in both human and poultry. Meanwhile, the...

  • ID BIOMEDICAL INITIATES STREPTAVAX CLINICAL TRIAL.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p1 

    No abstract available.

  • ID Biomedical gains NIH grant to develop nasally delivered plague vaccine.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p5 

    Reports that ID Biomedical has been awarded grant by the U.S. National Institutes of Health to develop a nasally delivered plague vaccine based on its proprietary, intranasal, Proteosome adjuvant/delivery technology. Aim to develop a sub-unit plague vaccine using a recombinant plague antigen,...

  • Infection control Update.  // Healthcare Purchasing News;Feb2005, Vol. 29 Issue 2, p26 

    Presents news briefs on the health care industry as of February 2005. Information on the safety-engineered BD Integra 1ml Retracting Tuberculin and Insulin Syringe released by Becton, Dickenson, and Company; Clearance received by ID Biomedical from the U.S. Food and Drug Administration to run a...

  • Facemasks, Hand Hygiene, and Influenza among Young Adults: A Randomized Intervention Trial. Aiello, Allison E.; Perez, Vanessa; Coulborn, Rebecca M.; Davis, Brian M.; Uddin, Monica; Monto, Arnold S. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Limited vaccine availability and the potential for resistance to antiviral medications have led to calls for establishing the efficacy of non-pharmaceutical measures formitigating pandemic influenza. Our objectivewas to examine if the use of facemasks and hand hygiene reduced rates of...

  • Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Stöhr, Klaus; Kieny, Marie-Paule; Wood, David // Nature Reviews Microbiology;Aug2006, Vol. 4 Issue 8, p565 

    Global access to an effective influenza vaccine will be essential in the event of a pandemic. Here, the WHO's Klaus Stöhr, Marie-Paule Kieny and David Wood argue that assessing the clinical benefits of low-dose H5N1 vaccines in animal models is crucial to achieving this goal.

  • PowderMed: flying ahead in avian flu.  // PharmaWatch: Monthly Review;Aug2006, Vol. 5 Issue 8, p37 

    The article reports that PowderMed Ltd. has submitted an application to Great Britain regulators seeking to conduct human trials of its avian influenza vaccine. PowderMed has applied to the British Medicines and Healthcare Products Regulatory Agency for permission to conduct a clinical trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics